Free Trial
→ Banks aren’t ready for this altcoin—are you? (From Crypto 101 Media) (Ad) Free AVDL Stock Alerts

Avadel Pharmaceuticals (AVDL) Financials

Avadel Pharmaceuticals logo
$10.83 -0.01 (-0.09%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$10.65 -0.18 (-1.70%)
As of 07/18/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Avadel Pharmaceuticals

Annual Income Statements for Avadel Pharmaceuticals

This table shows Avadel Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -85 42 -41 68 -95 -33 7.03 -77 -137 -160 -49
Consolidated Net Income / (Loss)		 -85 42 -41 68 -95 -33 7.03 -77 -137 -160 -49
Net Income / (Loss) Continuing Operations		 -89 42 -41 68 -95 -33 7.03 -77 -137 -160 -49
Total Pre-Tax Income 		-90 78 -9.72 93 -113 -39 -5.08 -93 -111 -161 -49
Total Operating Income		 -94 71 -4.97 90 -105 -24 5.82 -86 -99 -138 -42
Total Gross Profit		 12 162 137 157 86 47 17 0.00 0.00 27 154
Total Revenue		 15 173 150 173 103 59 22 0.00 0.00 28 169
Operating Revenue		 15 173 150 173 103 59 22 0.00 0.00 28 169
Total Cost of Revenue		 3.38 11 13 16 18 12 5.74 0.00 0.00 0.85 15
Operating Cost of Revenue		 3.38 11 13 16 18 12 5.74 0.00 0.00 0.85 15
Total Operating Expenses		 105 91 142 67 191 71 11 86 99 165 196
Selling, General & Admin Expense		 16 22 44 59 100 30 32 68 75 152 181
Research & Development Expense		 17 26 35 33 39 33 20 17 21 13 15
Restructuring Charge		 57 31 49 -28 -22 7.29 3.28 -0.05 3.35 0.00 0.00
Total Other Income / (Expense), net		 3.53 6.95 -4.75 3.16 -8.27 -14 -11 -7.60 -13 -23 -6.68
Interest Expense		 9.27 0.00 0.96 1.05 11 12 13 9.94 12 23 11
Interest & Investment Income		 0.93 1.24 2.76 2.14 0.45 -1.61 2.53 2.34 -0.54 0.09 4.15
Income Tax Expense		 -0.64 36 32 24 -18 -5.36 -12 -16 26 -0.50 -0.25
Basic Earnings per Share		 ($2.36) $1.03 ($1.00) $1.69 ($2.55) ($0.89) $0.13 ($1.32) ($2.29) ($2.00) ($0.51)
Weighted Average Basic Shares Outstanding		 36.21M 40.58M 41.25M 40.47M 37.33M 37.40M 53.00M 58.54M 60.09M 80.17M 95.14M
Diluted Earnings per Share		 ($2.36) $0.96 ($1.00) $1.63 ($2.55) ($0.89) $0.13 ($1.32) ($2.29) ($2.00) ($0.51)
Weighted Average Diluted Shares Outstanding		 36.21M 43.62M 41.25M 41.77M 37.33M 37.40M 54.94M 58.54M 60.09M 80.17M 95.14M
Weighted Average Basic & Diluted Shares Outstanding		 36.30M 41.80M 41.30M 40.40M 37.40M 46.40M 58.47M 59.03M 64.48M 90.58M 96.63M

Quarterly Income Statements for Avadel Pharmaceuticals

This table shows Avadel Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -20 -27 -31 -64 -36 -29 -27 -14 -2.63 -5.04 -4.92
Consolidated Net Income / (Loss)		 -20 -27 -31 -64 -36 -29 -27 -14 -2.63 -5.04 -4.92
Net Income / (Loss) Continuing Operations		 -20 -27 -31 -64 -36 -29 -27 -14 -2.63 -5.04 -4.92
Total Pre-Tax Income 		-20 -27 -31 -64 -36 -29 -27 -14 -2.54 -4.96 -4.84
Total Operating Income		 -17 -23 -28 -50 -35 -25 -26 -13 -0.33 -3.30 -3.00
Total Gross Profit		 0.00 - 0.00 1.46 6.90 19 26 39 44 46 47
Total Revenue		 0.00 - 0.00 1.50 7.01 19 27 42 50 50 53
Operating Revenue		 0.00 - 0.00 1.50 7.01 19 27 42 50 50 53
Total Cost of Revenue		 0.00 - 0.00 0.04 0.12 0.69 1.52 2.79 6.16 4.81 5.58
Operating Cost of Revenue		 0.00 - 0.00 0.04 0.12 0.69 1.52 2.79 6.16 4.81 5.58
Total Operating Expenses		 17 23 28 51 42 44 52 51 44 49 50
Selling, General & Admin Expense		 14 17 24 47 39 41 49 47 40 45 46
Research & Development Expense		 2.93 6.24 3.83 4.22 2.85 2.36 3.07 4.05 3.80 4.27 4.35
Total Other Income / (Expense), net		 -3.12 -4.33 -3.07 -15 -1.08 -3.99 -1.21 -1.59 -2.21 -1.67 -1.84
Interest Expense		 3.56 3.26 3.26 15 1.98 2.35 2.59 2.72 2.82 2.70 2.24
Interest & Investment Income		 0.45 -1.07 0.19 0.62 0.90 -1.63 1.38 1.13 0.61 1.04 0.40
Income Tax Expense		 0.07 0.09 -0.58 0.09 0.09 -0.10 0.09 -0.51 0.09 0.08 0.08
Basic Earnings per Share		 ($0.33) ($0.44) ($0.48) ($0.83) ($0.41) ($0.28) ($0.30) ($0.14) ($0.03) ($0.04) ($0.05)
Weighted Average Basic Shares Outstanding		 60.20M 60.09M 63.89M 77.25M 89.38M 80.17M 91.69M 96.15M 96.30M 95.14M 96.60M
Diluted Earnings per Share		 ($0.33) ($0.44) ($0.48) ($0.83) ($0.41) ($0.28) ($0.30) ($0.14) ($0.03) ($0.04) ($0.05)
Weighted Average Diluted Shares Outstanding		 60.20M 60.09M 63.89M 77.25M 89.38M 80.17M 91.69M 96.15M 96.30M 95.14M 96.60M
Weighted Average Basic & Diluted Shares Outstanding		 61.78M 64.48M 76.77M 89.37M 89.81M 90.58M 96.12M 96.27M 96.36M 96.63M 96.74M

Annual Cash Flow Statements for Avadel Pharmaceuticals

This table details how cash moves in and out of Avadel Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 33 25 -26 -23 -7.24 0.45 62 -21 23 -43 20
Net Cash From Operating Activities		 -11 84 19 17 -83 -38 -49 -77 -70 -129 -47
Net Cash From Continuing Operating Activities		 -11 84 19 17 -83 -38 -49 -77 -70 -129 -47
Net Income / (Loss) Continuing Operations		 -85 42 -41 68 -95 -33 7.03 -77 -137 -160 -49
Consolidated Net Income / (Loss)		 -85 42 -41 68 -95 -33 7.03 -77 -137 -160 -49
Depreciation Expense		 14 13 14 4.88 7.43 2.49 1.69 0.82 1.49 1.77 2.68
Amortization Expense		 - - 0.00 0.00 4.83 6.00 6.52 1.25 6.05 2.80 0.00
Non-Cash Adjustments To Reconcile Net Income		 55 34 49 -60 27 -9.24 -49 8.87 7.01 29 20
Changes in Operating Assets and Liabilities, net		 5.99 -4.53 -3.02 3.88 -27 -4.34 -15 -11 53 -1.74 -21
Net Cash From Investing Activities		 -43 -32 -37 -16 -37 39 -70 57 80 -50 52
Net Cash From Continuing Investing Activities		 -43 -32 -37 -16 -37 39 -70 57 80 -50 52
Purchase of Property, Plant & Equipment		 -1.73 -1.63 -1.20 -0.59 -0.18 -0.03 -0.10 -0.03 -0.72 0.00 0.00
Purchase of Investments		 -80 -78 -108 -151 -376 -25 -131 -62 -3.41 -237 -276
Sale and/or Maturity of Investments		 25 48 72 189 360 63 36 102 84 187 328
Net Cash From Financing Activities		 96 -24 -7.95 -23 113 -0.03 180 0.26 15 135 16
Net Cash From Continuing Financing Activities		 96 -24 -7.95 -23 113 -0.03 180 0.26 15 135 16
Repayment of Debt		 -35 -5.66 -0.28 -0.12 -6.94 -0.15 0.00 0.00 -13 -43 0.00
Issuance of Debt		 - - 0.00 0.00 144 - - 0.00 0.00 30 0.00
Issuance of Common Equity		 132 6.99 0.44 0.40 0.58 0.12 180 0.26 28 148 16
Other Net Changes in Cash		 - - - -0.30 - - - - -0.66 0.46 -0.64
Cash Interest Paid		 4.43 4.74 0.79 1.05 3.36 6.47 6.47 6.47 9.66 5.25 7.18
Cash Income Taxes Paid		 0.40 42 27 19 0.78 0.14 -1.70 0.08 -29 0.00 0.00

Quarterly Cash Flow Statements for Avadel Pharmaceuticals

This table details how cash moves in and out of Avadel Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 6.59 13 9.41 -33 1.83 -21 4.63 -6.95 -0.27 23 5.00
Net Cash From Operating Activities		 -6.80 -15 -30 -32 -38 -28 -30 -18 -6.89 7.87 -8.23
Net Cash From Continuing Operating Activities		 -6.80 -15 -30 -32 -38 -28 -30 -19 -6.44 7.87 -8.23
Net Income / (Loss) Continuing Operations		 -20 -27 -31 -64 -36 -29 -27 -14 -2.63 -5.04 -4.92
Consolidated Net Income / (Loss)		 -20 -27 -31 -64 -36 -29 -27 -14 -2.63 -5.04 -4.92
Depreciation Expense		 0.40 0.59 0.59 0.60 0.60 -0.02 0.54 0.44 1.04 0.67 0.83
Non-Cash Adjustments To Reconcile Net Income		 1.92 1.93 1.52 21 3.13 3.52 5.39 5.46 5.41 4.13 4.18
Changes in Operating Assets and Liabilities, net		 9.10 7.67 -3.43 10 -6.01 -2.74 -8.29 -11 -10 8.12 -8.32
Net Cash From Investing Activities		 2.52 23 5.07 -93 9.82 28 21 11 4.93 15 12
Net Cash From Continuing Investing Activities		 2.52 23 5.07 -93 9.82 28 21 11 4.93 15 12
Purchase of Investments		 -0.13 -1.08 -10 -103 -90 -34 -98 -78 -86 -14 -5.49
Sale and/or Maturity of Investments		 3.37 24 15 10 100 62 119 89 91 29 18
Net Cash From Financing Activities		 11 6.62 34 92 30 -21 13 0.72 1.18 0.88 0.69
Net Cash From Continuing Financing Activities		 11 6.62 34 92 30 -21 13 0.72 1.18 0.88 0.69
Issuance of Common Equity		 11 15 12 136 0.46 0.05 13 0.72 1.18 0.88 0.69
Effect of Exchange Rate Changes		 0.15 - 0.14 -0.02 -0.23 - -0.25 -0.03 0.52 - 0.22
Cash Interest Paid		 3.21 - 3.05 1.47 - 0.73 0.73 1.02 1.56 3.88 1.89

Annual Balance Sheets for Avadel Pharmaceuticals

This table presents Avadel Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 174 215 245 253 190 151 312 247 133 165 164
Total Current Assets		 112 166 181 124 125 82 263 192 101 134 134
Cash & Equivalents		 40 65 39 17 9.33 9.77 72 51 74 31 51
Short-Term Investments		 53 80 115 78 91 54 150 107 23 74 22
Accounts Receivable		 1.68 7.49 18 15 11 8.28 - - 0.00 12 34
Inventories, net		 6.73 3.67 3.26 6.16 4.77 3.57 - - 0.00 10 20
Prepaid Expenses		 4.42 8.06 5.89 8.96 8.55 4.26 39 33 2.10 6.61 6.04
Plant, Property, & Equipment, net		 1.78 2.62 3.32 3.00 1.91 0.54 0.36 0.29 0.84 0.59 0.45
Total Noncurrent Assets		 60 46 61 126 64 69 48 54 31 30 30
Goodwill		 18 18 18 18 18 18 17 17 17 17 17
Other Noncurrent Operating Assets		 0.13 0.17 7.53 10 36 43 28 36 13 13 13
Total Liabilities & Shareholders' Equity		 174 215 245 253 190 151 312 247 133 165 164
Total Liabilities		 149 146 203 168 188 181 149 169 154 77 90
Total Current Liabilities		 71 45 62 87 38 36 15 21 56 37 49
Accounts Payable		 8.02 30 41 32 13 12 2.93 7.68 7.89 11 7.33
Accrued Expenses		 5.67 9.31 17 51 22 20 6.50 7.15 7.33 24 41
Other Current Liabilities		 5.67 0.13 0.23 0.60 3.64 4.52 5.67 6.17 2.90 1.20 0.86
Total Noncurrent Liabilities		 78 101 141 81 149 145 134 148 98 40 42
Other Noncurrent Operating Liabilities		 77 2.53 5.28 7.08 14 11 6.05 5.62 6.52 40 42
Total Equity & Noncontrolling Interests		 25 69 42 86 2.78 -29 162 78 -21 88 74
Total Preferred & Common Equity		 25 69 42 86 2.78 -29 162 78 -21 88 74
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.05 0.00
Total Common Equity		 25 69 42 86 2.78 -29 162 78 -21 88 74
Common Stock		 353 370 385 394 434 435 567 550 590 856 893
Retained Earnings		 -320 -279 -320 -263 -358 -391 -384 -448 -585 -745 -794
Accumulated Other Comprehensive Income / (Loss)		 -7.42 -23 -24 -23 -23 -23 -21 -24 -26 -23 -25

Quarterly Balance Sheets for Avadel Pharmaceuticals

This table presents Avadel Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 158 146 141 201 203 168 158 158 168
Total Current Assets		 126 113 109 171 172 136 126 127 139
Cash & Equivalents		 54 61 83 50 52 36 29 29 56
Short-Term Investments		 50 46 18 111 101 53 43 37 10
Accounts Receivable		 - - - 1.78 6.24 23 33 37 42
Inventories, net		 - - - 1.44 5.29 12 13 16 20
Prepaid Expenses		 19 4.67 6.26 6.53 6.35 11 6.78 8.25 11
Plant, Property, & Equipment, net		 0.25 0.90 0.78 0.72 0.65 0.53 0.48 0.47 0.31
Total Noncurrent Assets		 32 32 30 29 30 31 31 31 28
Goodwill		 17 17 17 17 17 17 17 17 17
Other Noncurrent Operating Assets		 14 14 12 12 13 14 14 14 12
Total Liabilities & Shareholders' Equity		 158 146 141 201 203 168 158 158 168
Total Liabilities		 161 158 179 58 93 90 87 84 94
Total Current Liabilities		 46 42 79 52 54 48 45 43 51
Accounts Payable		 7.32 2.48 10 12 13 19 9.79 7.92 9.12
Accrued Expenses		 9.68 7.97 7.68 18 18 28 34 34 41
Other Current Liabilities		 2.98 4.77 41 1.28 1.65 1.21 1.11 0.96 0.90
Total Noncurrent Liabilities		 115 117 100 6.28 39 42 43 41 43
Other Noncurrent Operating Liabilities		 6.98 6.75 6.41 6.28 39 42 43 41 43
Total Equity & Noncontrolling Interests		 -3.33 -12 -38 143 110 78 70 75 74
Total Preferred & Common Equity		 -3.33 -12 -38 143 110 78 70 75 74
Preferred Stock		 0.01 0.01 0.01 0.05 0.05 0.00 0.00 0.00 0.00
Total Common Equity		 -3.34 -12 -38 143 110 78 70 75 74
Common Stock		 561 573 604 850 853 875 881 888 898
Retained Earnings		 -538 -558 -616 -680 -717 -773 -787 -789 -799
Accumulated Other Comprehensive Income / (Loss)		 -26 -28 -26 -26 -26 -24 -24 -24 -24

Annual Metrics And Ratios for Avadel Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Avadel Pharmaceuticals' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 258.34% 1,055.32% -13.16% 15.31% -40.39% -42.66% -62.28% -100.00% 0.00% 0.00% 504.79%
EBITDA Growth		 -36.27% 232.46% -96.68% 3,141.23% -194.10% 82.36% 184.91% -714.12% -9.02% -46.44% 70.20%
EBIT Growth		 -53.11% 193.50% -115.06% 895.41% -212.50% 76.23% 121.97% -1,690.07% -15.21% -39.86% 69.24%
NOPAT Growth		 -74.41% 158.06% -109.13% 1,997.47% -211.38% 77.02% 124.12% -1,571.13% -15.21% -39.86% 69.24%
Net Income Growth		 -99.11% 148.90% -198.75% 265.40% -239.60% 65.14% 121.15% -1,200.30% -77.77% -16.59% 69.53%
EPS Growth		 -39.65% 140.68% -204.17% 263.00% -256.44% 65.10% 114.61% -1,115.38% -73.48% 12.66% 74.50%
Operating Cash Flow Growth		 48.65% 893.94% -77.58% -11.85% -596.44% 53.67% -27.16% -58.64% 9.06% -82.79% 63.50%
Free Cash Flow Firm Growth		 163.69% -127.57% 55.01% 648.64% -290.19% 58.85% -31.93% -117.77% 68.26% -292.11% 30.17%
Invested Capital Growth		 -132.71% 192.15% 4.01% 175.33% -41.99% 5.24% 72.25% -8.19% -81.65% -249.27% 100.41%
Revenue Q/Q Growth		 0.00% 0.00% -0.85% -4.59% -11.81% -14.35% -32.99% 0.00% 0.00% 228.59% 22.41%
EBITDA Q/Q Growth		 0.00% 0.00% -95.18% -18.83% -315.90% 80.68% -34.99% -14.56% 2.23% -3.39% 35.95%
EBIT Q/Q Growth		 0.00% 0.00% -124.58% -19.13% -211.54% 73.44% -56.65% -11.82% 0.10% -1.37% 33.75%
NOPAT Q/Q Growth		 0.00% 0.00% -112.29% -14.60% -212.42% 73.84% -54.31% -11.58% 0.10% -1.37% 33.75%
Net Income Q/Q Growth		 0.00% 0.00% -241.97% -15.97% -140.12% 62.20% -22.96% -16.62% -3.89% -0.84% 32.72%
EPS Q/Q Growth		 0.00% 0.00% -244.93% -15.10% -150.00% 0.00% 0.00% -22.22% -2.69% 7.41% 32.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -49.68% -56.40% -14.87% 29.81% -28.71% -4.57% 9.22% -10.93% 43.36%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -55.70% 5.03% -12.91% -8.80% -15.49% 34.88% -20.44% 37.59%
Invested Capital Q/Q Growth		 0.00% 0.00% -32.05% 13.46% -53.91% 15.01% 3.62% 5.79% -32.80% 20.47% -99.20%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 77.41% 93.41% 91.18% 90.59% 83.04% 79.52% 74.29% 0.00% 0.00% 96.97% 90.97%
EBITDA Margin		 -451.72% 51.79% 1.98% 55.68% -87.89% -27.04% 60.87% 0.00% 0.00% -476.65% -23.49%
Operating Margin		 -625.42% 40.90% -3.30% 51.66% -101.60% -40.72% 26.04% 0.00% 0.00% -492.97% -25.07%
EBIT Margin		 -546.15% 44.20% -7.66% 52.86% -99.77% -41.36% 24.09% 0.00% 0.00% -492.97% -25.07%
Profit (Net Income) Margin		 -570.74% 24.16% -27.47% 39.41% -92.29% -56.11% 31.47% 0.00% 0.00% -573.17% -28.87%
Tax Burden Percent		 94.83% 53.79% 424.74% 73.68% 84.19% 86.12% -138.29% 83.02% 123.35% 99.69% 99.50%
Interest Burden Percent		 110.20% 101.62% 84.41% 101.18% 109.87% 157.54% -94.46% 108.88% 113.07% 116.63% 115.76%
Effective Tax Rate		 0.00% 46.21% 0.00% 26.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -256.03% 0.00% -14.85% 147.29% -141.52% -43.16% 7.46% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -367.16% 0.00% 102.53% 135.08% -424.70% -74.41% -17.30% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -855.19% 0.00% -59.38% -40.32% -74.19% 294.69% 3.11% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -1,111.21% 88.90% -74.24% 106.97% -215.72% 251.53% 10.56% -64.30% -481.49% -481.35% -60.44%
Cash Return on Invested Capital (CROIC)		 0.00% -42.59% -18.79% 53.86% -88.37% -48.27% -45.62% -81.86% -45.86% 0.00% -66,369.44%
Operating Return on Assets (OROA)		 -56.32% 39.29% -5.00% 36.72% -46.45% -14.33% 2.32% 0.00% 0.00% -92.68% -25.78%
Return on Assets (ROA)		 -58.85% 21.47% -17.92% 27.38% -42.97% -19.45% 3.04% 0.00% 0.00% -107.75% -29.69%
Return on Common Equity (ROCE)		 -1,111.21% 88.90% -74.24% 106.97% -215.72% 251.53% 10.56% -64.30% -481.41% -480.94% -60.42%
Return on Equity Simple (ROE_SIMPLE)		 -343.32% 60.46% -98.12% 79.77% -3,428.20% 113.79% 4.33% -98.83% 650.10% -182.67% -66.13%
Net Operating Profit after Tax (NOPAT)		 -66 38 -3.48 66 -73 -17 4.07 -60 -69 -96 -30
NOPAT Margin		 -437.80% 22.00% -2.31% 38.07% -71.12% -28.50% 18.23% 0.00% 0.00% -345.08% -17.55%
Net Nonoperating Expense Percent (NNEP)		 111.13% 7.79% -117.38% 12.20% 283.18% 31.25% 24.76% -32.30% 762.53% -176.37% -21.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -63.80% -109.98% -40.19%
Cost of Revenue to Revenue		 22.59% 6.60% 8.82% 9.41% 16.96% 20.48% 25.71% 0.00% 0.00% 3.03% 9.03%
SG&A Expenses to Revenue		 104.83% 12.55% 29.40% 33.98% 97.18% 50.97% 145.09% 0.00% 0.00% 542.52% 107.05%
R&D to Revenue		 115.51% 14.80% 23.04% 19.29% 38.08% 55.59% 91.53% 0.00% 0.00% 47.42% 8.99%
Operating Expenses to Revenue		 702.83% 52.51% 94.49% 38.93% 184.64% 120.24% 48.25% 0.00% 0.00% 589.94% 116.04%
Earnings before Interest and Taxes (EBIT)		 -82 76 -12 92 -103 -24 5.38 -86 -99 -138 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -68 90 2.98 96 -91 -16 14 -83 -91 -133 -40
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 17.62 7.10 10.19 3.81 34.35 0.00 2.40 6.05 0.00 0.00 13.71
Price to Tangible Book Value (P/TBV)		 0.00 14.09 578.27 0.00 0.00 0.00 2.68 7.71 0.00 0.00 17.76
Price to Revenue (P/Rev)		 29.30 2.84 2.85 1.88 0.92 4.78 17.43 0.00 0.00 0.00 5.99
Price to Earnings (P/E)		 0.00 11.74 0.00 4.78 0.00 0.00 55.39 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 8.52% 0.00% 20.94% 0.00% 0.00% 1.81% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 15.13 11.53 3.54 2.92 8.49 4.29 7.23 0.00 0.00 13,225.11
Enterprise Value to Revenue (EV/Rev)		 26.01 2.01 1.83 1.34 1.08 5.75 13.26 0.00 0.00 0.00 5.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 3.87 92.45 2.41 0.00 0.00 21.78 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 4.54 0.00 2.54 0.00 0.00 55.03 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 9.12 0.00 3.52 0.00 0.00 72.74 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 4.12 14.56 13.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 10.99 0.00 0.00 9.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.75 0.02 0.02 0.00 41.67 -4.17 0.79 1.82 -6.11 0.00 0.00
Long-Term Debt to Equity		 0.05 0.01 0.01 0.00 41.63 -4.17 0.79 1.82 -4.33 0.00 0.00
Financial Leverage		 2.33 -1.02 -0.58 -0.30 0.17 -3.96 -0.18 -0.45 0.31 -1.09 -1.11
Leverage Ratio		 18.88 4.14 4.14 3.91 5.02 -12.94 3.48 2.32 6.66 4.47 2.04
Compound Leverage Factor		 20.81 4.21 3.50 3.95 5.52 -20.38 -3.29 2.53 7.53 5.21 2.36
Debt to Total Capital		 63.66% 1.59% 1.90% 0.31% 97.66% 131.57% 44.14% 64.54% 119.55% 0.00% 0.00%
Short-Term Debt to Total Capital		 61.79% 0.62% 0.62% 0.13% 0.09% 0.00% 0.00% 0.00% 34.83% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.86% 0.97% 1.28% 0.18% 97.57% 131.57% 44.14% 64.54% 84.72% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.06% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 36.34% 98.41% 98.10% 99.69% 2.34% -31.57% 55.86% 35.46% -19.56% 99.94% 100.00%
Debt to EBITDA		 -0.64 0.01 0.27 0.00 -1.28 -7.60 9.43 -1.71 -1.42 0.00 0.00
Net Debt to EBITDA		 0.73 -1.60 -51.54 -0.97 -0.18 -3.59 -6.86 0.18 -0.36 0.00 0.00
Long-Term Debt to EBITDA		 -0.02 0.01 0.18 0.00 -1.28 -7.60 9.43 -1.71 -1.01 0.00 0.00
Debt to NOPAT		 -0.67 0.03 -0.23 0.00 -1.58 -7.21 31.50 -2.38 -1.87 0.00 0.00
Net Debt to NOPAT		 0.75 -3.78 44.13 -1.42 -0.22 -3.41 -22.89 0.25 -0.48 0.00 0.00
Long-Term Debt to NOPAT		 -0.02 0.02 -0.16 0.00 -1.58 -7.21 31.50 -2.38 -1.33 0.00 0.00
Altman Z-Score		 -1.99 2.86 0.48 1.77 -3.03 -2.45 0.92 -1.16 0.00 0.00 0.75
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.09% 0.03%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.59 3.68 2.90 1.43 3.25 2.29 17.44 9.17 1.81 3.64 2.75
Quick Ratio		 1.33 3.37 2.76 1.26 2.90 2.01 14.65 7.49 1.73 3.18 2.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 35 -9.77 -4.40 24 -46 -19 -25 -54 -17 -67 -47
Operating Cash Flow to CapEx		 0.00% 5,174.52% 1,573.77% 2,819.29% -46,469.66% 0.00% -49,728.57% -297,346.15% -9,818.99% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 3.82 0.00 -4.56 22.92 -4.32 -1.51 -1.92 -5.45 -1.39 -2.93 -4.35
Operating Cash Flow to Interest Expense		 -1.15 0.00 19.63 15.84 -7.79 -3.07 -3.75 -7.78 -5.70 -5.58 -4.33
Operating Cash Flow Less CapEx to Interest Expense		 0.10 0.00 18.38 15.28 -7.80 -3.06 -3.76 -7.78 -5.75 -5.58 -4.33
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.10 0.89 0.65 0.69 0.47 0.35 0.10 0.00 0.00 0.19 1.03
Accounts Receivable Turnover		 3.80 37.75 11.87 10.62 7.91 6.04 0.00 0.00 0.00 0.00 7.32
Inventory Turnover		 0.74 2.20 3.83 3.46 3.21 2.91 0.00 0.00 0.00 0.00 1.00
Fixed Asset Turnover		 7.19 78.78 50.62 54.82 42.05 48.24 49.47 0.00 0.00 39.27 325.85
Accounts Payable Turnover		 0.52 0.60 0.37 0.44 0.77 0.99 0.79 0.00 0.00 0.09 1.63
Days Sales Outstanding (DSO)		 96.07 9.67 30.76 34.37 46.15 60.44 0.00 0.00 0.00 0.00 49.86
Days Inventory Outstanding (DIO)		 493.01 166.27 95.38 105.41 113.85 125.53 0.00 0.00 0.00 0.00 366.48
Days Payable Outstanding (DPO)		 707.94 612.21 985.43 825.86 473.30 370.21 463.66 0.00 0.00 4,168.38 224.12
Cash Conversion Cycle (CCC)		 -118.85 -436.28 -859.28 -686.08 -313.30 -184.24 -463.66 0.00 0.00 -4,168.38 192.22
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -25 23 24 66 38 40 69 63 12 -17 0.07
Invested Capital Turnover		 0.58 -177.17 6.42 3.87 1.99 1.51 0.41 0.00 0.00 -9.75 -19.55
Increase / (Decrease) in Invested Capital		 -101 48 0.92 42 -28 2.00 29 -5.65 -52 -29 17
Enterprise Value (EV)		 390 347 275 232 111 340 296 459 0.00 0.00 939
Market Capitalization		 439 491 428 326 95 283 389 474 0.00 0.00 1,013
Book Value per Share		 $0.97 $1.72 $1.02 $2.15 $0.08 ($0.78) $2.78 $1.33 ($0.34) $0.98 $0.77
Tangible Book Value per Share		 ($0.86) $0.87 $0.02 ($0.63) ($0.47) ($1.30) $2.50 $1.05 ($0.61) $0.79 $0.59
Total Capital		 69 70 43 86 119 92 290 221 108 88 74
Total Debt		 44 1.12 0.82 0.27 116 122 128 142 129 0.00 0.00
Total Long-Term Debt		 1.28 0.68 0.55 0.16 116 122 128 142 92 0.00 0.00
Net Debt		 -49 -144 -153 -94 16 58 -93 -15 33 -105 -74
Capital Expenditures (CapEx)		 -12 1.63 1.20 0.59 0.18 -0.13 0.10 0.03 0.72 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.02 -23 -35 -57 -13 -18 27 14 -14 -7.76 12
Debt-free Net Working Capital (DFNWC)		 84 122 119 38 87 46 248 171 83 97 85
Net Working Capital (NWC)		 41 121 119 37 86 46 248 171 45 97 85
Net Nonoperating Expense (NNE)		 20 -3.74 38 -2.32 22 16 -2.96 17 68 64 19
Net Nonoperating Obligations (NNO)		 -50 -46 -18 -20 35 69 -93 -15 33 -105 -74
Total Depreciation and Amortization (D&A)		 14 13 14 4.88 12 8.48 8.21 2.06 7.55 4.56 2.68
Debt-free, Cash-free Net Working Capital to Revenue		 -60.25% -13.42% -23.40% -32.63% -12.92% -30.00% 120.64% 0.00% 0.00% -27.77% 6.86%
Debt-free Net Working Capital to Revenue		 559.68% 70.28% 79.23% 21.67% 83.83% 78.35% 1,111.96% 0.00% 0.00% 348.13% 50.48%
Net Working Capital to Revenue		 277.00% 70.03% 79.05% 21.61% 83.73% 78.35% 1,111.96% 0.00% 0.00% 348.13% 50.48%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $1.00 ($1.00) $1.69 ($2.55) ($0.89) $0.13 ($1.32) ($2.29) ($2.00) ($0.51)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 40.58M 41.25M 40.47M 37.33M 37.40M 53.00M 58.54M 60.09M 80.17M 95.14M
Adjusted Diluted Earnings per Share		 $0.00 $0.93 ($1.00) $1.63 ($2.55) ($0.89) $0.13 ($1.32) ($2.29) ($2.00) ($0.51)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 43.62M 41.25M 41.77M 37.33M 37.40M 54.94M 58.54M 60.09M 80.17M 95.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 40.23M 41.38M 37.95M 37.36M 46.40M 58.47M 59.03M 64.48M 90.58M 96.63M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 55 31 45 -42 -12 6.37 -60 -67 -96 -30
Normalized NOPAT Margin		 -169.06% 31.62% 20.65% 25.95% -41.05% -19.89% 28.52% 0.00% 0.00% -345.08% -17.55%
Pre Tax Income Margin		 -601.88% 44.91% -6.47% 53.48% -109.61% -65.16% -22.75% 0.00% 0.00% -574.96% -29.02%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -8.82 0.00 -11.96 87.05 -9.70 -1.96 0.41 -8.60 -7.99 -5.99 -3.92
NOPAT to Interest Expense		 -7.07 0.00 -3.61 62.69 -6.91 -1.35 0.31 -6.02 -5.59 -4.19 -2.74
EBIT Less CapEx to Interest Expense		 -7.58 0.00 -13.20 86.49 -9.72 -1.95 0.41 -8.61 -8.04 -5.99 -3.92
NOPAT Less CapEx to Interest Expense		 -5.83 0.00 -4.86 62.12 -6.93 -1.34 0.31 -6.03 -5.65 -4.19 -2.74
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 32.75% -29.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Avadel Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Avadel Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,674.33% 613.22% 159.14% 93.21%
EBITDA Growth		 41.79% 9.18% 7.91% -74.10% -133.45% -21.27% 1.33% 74.55% 102.07% 89.45% 91.46%
EBIT Growth		 33.91% 0.42% 1.15% -65.48% -107.02% -8.08% 8.00% 74.28% 99.07% 86.76% 88.47%
NOPAT Growth		 33.91% 0.42% 1.15% -65.48% -107.02% -8.08% 8.00% 74.28% 99.07% 86.76% 88.47%
Net Income Growth		 8.44% -23.09% -16.50% -1.56% -80.06% -4.87% 11.18% 78.55% 92.76% 82.48% 82.01%
EPS Growth		 13.16% -15.79% -6.67% 22.43% -24.24% 36.36% 37.50% 83.13% 92.68% 85.71% 83.33%
Operating Cash Flow Growth		 67.97% 31.72% 11.20% -127.27% -461.90% -82.41% 1.75% 43.21% 81.98% 128.09% 72.29%
Free Cash Flow Firm Growth		 373.42% 438.25% 472.35% -213.58% -52.59% -67.52% -141.52% 62.19% -312.07% -270.55% 39.58%
Invested Capital Growth		 -71.11% -81.65% -134.16% -86.85% -226.13% -249.27% 59.09% -130.97% 140.54% 100.41% 172.91%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 368.85% 177.35% 39.71% 52.71% 20.53% 0.77% 4.17%
EBITDA Q/Q Growth		 47.28% -40.34% -25.75% -87.15% 29.31% 27.10% -2.31% 51.74% 105.75% -471.19% 17.20%
EBIT Q/Q Growth		 43.35% -35.84% -22.83% -75.07% 29.13% 29.08% -4.56% 51.06% 97.43% -907.95% 8.95%
NOPAT Q/Q Growth		 43.35% -35.84% -22.83% -75.07% 29.13% 29.08% -4.56% 51.06% 97.43% -907.95% 8.95%
Net Income Q/Q Growth		 68.25% -36.26% -12.15% -109.30% 43.70% 20.64% 5.02% 49.45% 81.01% -92.11% 2.44%
EPS Q/Q Growth		 69.16% -33.33% -9.09% -72.92% 50.60% 31.71% -7.14% 53.33% 78.57% -33.33% -25.00%
Operating Cash Flow Q/Q Growth		 51.72% -125.87% -96.75% -5.92% -19.37% 26.68% -5.98% 38.78% 62.11% 214.27% -204.56%
Free Cash Flow Firm Q/Q Growth		 207.81% 15.91% 124.61% -114.17% 228.50% -20.60% -387.17% 87.09% -620.64% 36.14% -1.73%
Invested Capital Q/Q Growth		 -35.53% -32.80% -318.55% 113.89% -718.26% 20.47% 40.10% 89.49% 909.51% -99.20% 10,584.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 97.59% 98.33% 96.44% 94.40% 93.28% 87.70% 90.45% 89.38%
EBITDA Margin		 0.00% 0.00% 0.00% -3,232.15% -487.30% -128.09% -93.80% -29.65% 1.42% -5.21% -4.14%
Operating Margin		 0.00% 0.00% 0.00% -3,311.56% -500.57% -128.00% -95.79% -30.70% -0.65% -6.54% -5.72%
EBIT Margin		 0.00% 0.00% 0.00% -3,311.56% -500.57% -128.00% -95.79% -30.70% -0.65% -6.54% -5.72%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -4,306.95% -517.17% -147.98% -100.60% -33.30% -5.25% -10.00% -9.37%
Tax Burden Percent		 100.35% 100.31% 98.15% 100.14% 100.25% 99.65% 100.34% 96.45% 103.47% 101.63% 101.61%
Interest Burden Percent		 118.37% 118.78% 110.83% 129.88% 103.06% 116.01% 104.66% 112.48% 775.84% 150.55% 161.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -228.19% 0.00% 0.00% 0.00% -1,676.62% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -173.83% 0.00% 0.00% 0.00% -1,671.97% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 136.05% 0.00% 0.00% 0.00% 1,652.87% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -305.87% -481.49% -1,662.06% -92.14% -325.33% -481.35% -779.92% -23.75% -78.54% -60.44% -34.65%
Cash Return on Invested Capital (CROIC)		 -68.41% -45.86% 0.00% -389.25% 0.00% 0.00% 0.00% 0.00% -852.54% -66,369.44% -415.85%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -27.61% -24.42% -24.06% -34.23% -16.30% -0.50% -6.72% -6.62%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -35.90% -25.23% -27.82% -35.95% -17.68% -4.01% -10.29% -10.85%
Return on Common Equity (ROCE)		 -305.84% -481.41% -1,661.09% -92.10% -325.14% -480.94% -779.82% -23.74% -78.52% -60.42% -34.65%
Return on Equity Simple (ROE_SIMPLE)		 1,063.63% 0.00% 371.60% -99.73% -144.30% 0.00% -200.08% -151.13% -97.20% 0.00% -35.66%
Net Operating Profit after Tax (NOPAT)		 -12 -16 -20 -35 -25 -17 -18 -8.92 -0.23 -2.31 -2.10
NOPAT Margin		 0.00% 0.00% 0.00% -2,318.09% -350.40% -89.60% -67.06% -21.49% -0.46% -4.58% -4.00%
Net Nonoperating Expense Percent (NNEP)		 -178.92% 126.10% 68.68% -54.36% -22.88% -31.40% -23.98% -4.65% -2.42% -3.06% -3.63%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.91% - - - -19.87% - - - -3.12% -2.84%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 2.41% 1.67% 3.56% 5.60% 6.72% 12.30% 9.55% 10.62%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 3,126.87% 558.28% 212.31% 178.91% 114.22% 80.75% 88.51% 86.80%
R&D to Revenue		 0.00% 0.00% 0.00% 282.29% 40.62% 12.13% 11.29% 9.76% 7.60% 8.48% 8.29%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 3,409.16% 598.90% 224.44% 190.19% 123.98% 88.35% 96.99% 95.09%
Earnings before Interest and Taxes (EBIT)		 -17 -23 -28 -50 -35 -25 -26 -13 -0.33 -3.30 -3.00
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -21 -26 -48 -34 -25 -25 -12 0.71 -2.63 -2.18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.23 16.91 13.71 10.21
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 25.28 21.83 17.76 13.22
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14.20 9.14 5.99 3.89
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 19.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 135.14 13,225.11 90.97
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.45 8.66 5.55 3.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -10.95 -6.11 -2.98 0.15 0.19 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 -8.84 -4.33 -2.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.11 0.31 1.87 -0.78 -1.05 -1.09 -1.89 -0.99 -1.07 -1.11 -1.02
Leverage Ratio		 4.74 6.66 21.20 2.57 3.57 4.47 7.67 1.68 1.96 2.04 2.20
Compound Leverage Factor		 5.61 7.91 23.50 3.33 3.68 5.18 8.03 1.89 15.17 3.06 3.55
Debt to Total Capital		 110.05% 119.55% 150.56% 12.71% 16.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 21.24% 34.83% 27.18% 12.71% 16.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 88.80% 84.72% 123.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.01% 0.03% 0.04% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -10.05% -19.56% -50.57% 87.26% 83.83% 99.94% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.46 -1.42 -1.28 -0.19 -0.16 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.32 -0.36 -0.14 1.28 1.02 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -1.18 -1.01 -1.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.97 -1.87 -1.65 -0.25 -0.22 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -0.43 -0.48 -0.19 1.69 1.39 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -1.59 -1.33 -1.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -4.01 0.00 0.00 0.00 0.00 0.00 0.00 3.26 3.59 1.54 -0.10
Noncontrolling Interest Sharing Ratio		 0.01% 0.02% 0.06% 0.04% 0.06% 0.09% 0.01% 0.02% 0.03% 0.03% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.73 1.81 1.38 3.32 3.19 3.64 2.85 2.82 2.97 2.75 2.73
Quick Ratio		 2.57 1.73 1.27 3.15 2.95 3.18 2.33 2.35 2.41 2.21 2.12
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 31 36 80 -11 15 12 -33 -4.29 -31 -20 -20
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 8.63 10.95 24.57 -0.74 7.37 4.92 -12.83 -1.58 -10.97 -7.31 -8.98
Operating Cash Flow to Interest Expense		 -1.91 -4.72 -9.28 -2.08 -19.33 -11.91 -11.46 -6.70 -2.44 2.91 -3.68
Operating Cash Flow Less CapEx to Interest Expense		 -1.91 -4.72 -9.28 -2.08 -19.33 -11.91 -11.46 -6.70 -2.44 2.91 -3.68
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.01 0.05 0.19 0.36 0.53 0.76 1.03 1.16
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.41 6.38 7.32 6.05
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.69 1.04 1.00 1.20
Fixed Asset Turnover		 0.00 0.00 0.00 3.09 11.02 39.27 84.31 158.71 247.38 325.85 466.87
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.02 0.09 0.16 0.47 1.05 1.63 1.38
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 67.42 57.25 49.86 60.32
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 525.83 349.74 366.48 305.24
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 96,846.67 18,777.22 4,168.38 2,233.78 769.21 346.42 224.12 265.06
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -96,846.67 -18,777.22 -4,168.38 -2,233.78 -175.96 60.57 192.22 100.51
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 17 12 -25 3.53 -22 -17 -10 -1.09 8.86 0.07 7.59
Invested Capital Turnover		 0.00 0.00 0.00 0.10 -3.76 -9.75 -3.08 78.02 -21.28 -19.55 -137.96
Increase / (Decrease) in Invested Capital		 -43 -52 -100 -23 -39 -29 15 -4.63 31 17 18
Enterprise Value (EV)		 329 0.00 0.00 0.00 0.00 0.00 0.00 1,280 1,197 939 690
Market Capitalization		 300 0.00 0.00 0.00 0.00 0.00 0.00 1,351 1,263 1,013 757
Book Value per Share		 ($0.21) ($0.34) ($0.59) $1.86 $1.23 $0.98 $0.87 $0.73 $0.78 $0.77 $0.77
Tangible Book Value per Share		 ($0.49) ($0.61) ($0.85) $1.65 $1.04 $0.79 $0.68 $0.56 $0.60 $0.59 $0.59
Total Capital		 124 108 75 164 131 88 78 70 75 74 74
Total Debt		 136 129 114 21 21 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 110 92 93 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 30 33 13 -140 -132 -105 -89 -71 -66 -74 -66
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.47 -14 -50 -20 -14 -7.76 -0.56 9.79 19 12 22
Debt-free Net Working Capital (DFNWC)		 98 83 51 141 139 97 88 81 84 85 88
Net Working Capital (NWC)		 72 45 30 120 118 97 88 81 84 85 88
Net Nonoperating Expense (NNE)		 8.27 11 11 30 12 11 9.12 4.90 2.40 2.74 2.82
Net Nonoperating Obligations (NNO)		 30 33 13 -140 -132 -105 -89 -71 -66 -74 -66
Total Depreciation and Amortization (D&A)		 2.32 2.49 2.46 1.19 0.93 -0.02 0.54 0.44 1.04 0.67 0.83
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -1,332.29% -162.06% -27.77% -1.02% 10.28% 13.51% 6.86% 11.23%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 9,396.99% 1,637.93% 348.13% 160.00% 85.31% 61.14% 50.48% 45.42%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 8,003.21% 1,388.97% 348.13% 160.00% 85.31% 61.14% 50.48% 45.42%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.33) ($0.44) ($0.48) ($0.83) ($0.41) ($0.28) ($0.30) ($0.14) ($0.03) ($0.04) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 60.20M 60.09M 63.89M 77.25M 89.38M 80.17M 91.69M 96.15M 96.30M 95.14M 96.60M
Adjusted Diluted Earnings per Share		 ($0.33) ($0.44) ($0.48) ($0.83) ($0.41) ($0.28) ($0.30) ($0.14) ($0.03) ($0.04) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 60.20M 60.09M 63.89M 77.25M 89.38M 80.17M 91.69M 96.15M 96.30M 95.14M 96.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 61.78M 64.48M 76.77M 89.37M 89.81M 90.58M 96.12M 96.27M 96.36M 96.63M 96.74M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -16 -20 -35 -25 -17 -18 -8.92 -0.23 -2.31 -2.10
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -2,318.09% -350.40% -89.60% -67.06% -21.49% -0.46% -4.58% -4.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -4,300.94% -515.90% -148.49% -100.26% -34.53% -5.07% -9.84% -9.22%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.76 -7.08 -8.68 -3.21 -17.75 -10.58 -10.04 -4.69 -0.12 -1.22 -1.34
NOPAT to Interest Expense		 -3.33 -4.95 -6.08 -2.25 -12.43 -7.40 -7.03 -3.28 -0.08 -0.85 -0.94
EBIT Less CapEx to Interest Expense		 -4.76 -7.08 -8.68 -3.21 -17.75 -10.58 -10.04 -4.69 -0.12 -1.22 -1.34
NOPAT Less CapEx to Interest Expense		 -3.33 -4.95 -6.08 -2.25 -12.43 -7.40 -7.03 -3.28 -0.08 -0.85 -0.94
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Avadel Pharmaceuticals (NASDAQ:AVDL) reported its Q1 2025 results with continued top‐line growth, solid liquidity and a high gross margin, though profitability and cash burn remain challenges. Below are the key takeaways from the latest quarter and recent trends.

  • Operating revenue rose to $52.5 M in Q1 2025, up 4.2% sequentially and 93.2% year-over-year, marking the fourth consecutive quarter of revenue growth.
  • Cash & equivalents climbed to $56.4 M at the end of Q1 2025, up from $28.6 M in Q3 2024, providing a strong liquidity buffer.
  • Gross margin held at 89.4% in Q1 2025, reflecting efficient control of cost of revenue despite higher volumes and investments.
  • Net cash from investing activities was +$12.3 M in Q1 2025, driven by the sale/maturity of short-term investments, helping offset operating cash outflows.
  • SG&A and R&D expenses remained high at 95% of revenue in Q1 2025, underscoring ongoing investment in commercialization and pipeline development.
  • Interest expense of $2.2 M in Q1 2025 was largely offset by $0.4 M of interest income, resulting in a net interest burden that remains a modest drag.
  • Net loss narrowed slightly to −$4.9 M in Q1 2025 from −$5.0 M in Q4 2024, indicating a modest improvement in operating performance.
  • Free Cash Flow to Firm (FCFF) was −$20.1 M in Q1 2025, reflecting continued cash burn as the company invests in growth.
  • Operating income remained negative at −$3.0 M in Q1 2025, highlighting that the business is not yet profitable on an operating basis.
  • Altman Z-Score stood at −0.10 for Q1 2025, suggesting potential financial distress if losses and cash burn persist.
07/19/25 01:57 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Avadel Pharmaceuticals' Financials

When does Avadel Pharmaceuticals' fiscal year end?

According to the most recent income statement we have on file, Avadel Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Avadel Pharmaceuticals' net income changed over the last 10 years?

Avadel Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$48.83 million in 2024, falling from -$85.47 million in 2014. The previous period was -$160.28 million in 2023. Check out Avadel Pharmaceuticals' forecast to explore projected trends and price targets.

What is Avadel Pharmaceuticals' operating income?
Avadel Pharmaceuticals' total operating income in 2024 was -$42.40 million, based on the following breakdown:
  • Total Gross Profit: $153.84 million
  • Total Operating Expenses: $196.24 million
How has Avadel Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, Avadel Pharmaceuticals' total revenue changed from $14.98 million in 2014 to $169.12 million in 2024, a change of 1,029.3%.

How much debt does Avadel Pharmaceuticals have?

Avadel Pharmaceuticals' total liabilities were at $90.39 million at the end of 2024, a 17.4% increase from 2023, and a 39.5% decrease since 2014.

How much cash does Avadel Pharmaceuticals have?

In the past 10 years, Avadel Pharmaceuticals' cash and equivalents has ranged from $9.33 million in 2018 to $73.98 million in 2022, and is currently $51.37 million as of their latest financial filing in 2024.

How has Avadel Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Avadel Pharmaceuticals' book value per share changed from 0.97 in 2014 to 0.77 in 2024, a change of -21.2%.


Related Companies

This page (NASDAQ:AVDL) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...
Paradigm Press | Sponsored
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsored
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Turn $1K into $50K with This DeFi Gem
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...
Crypto 101 Media | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored